Description and Brand Names
US Brand Name
Ibrutinib is used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) in patients with 17p deletion, Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). It is also used to treat chronic graft-versus-host disease (cGHVD) after one or more lines of treatment did not work. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Ibrutinib is an antineoplastic agent (cancer medicine).
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms: